JP2003510029A5 - - Google Patents

Info

Publication number

JP2003510029A5

JP2003510029A5 JP2001518744A JP2001518744A JP2003510029A5 JP 2003510029 A5 JP2003510029 A5 JP 2003510029A5 JP 2001518744 A JP2001518744 A JP 2001518744A JP 2001518744 A JP2001518744 A JP 2001518744A JP 2003510029 A5 JP2003510029 A5 JP 2003510029A5

Authority

JP

Japan

Prior art keywords

composition

polypeptide

seq

amino acids

polynucleotide

Prior art date

2000-08-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 229920001184 polypeptide Polymers 0.000 description 35
• 102000004196 processed proteins & peptides Human genes 0.000 description 35
• 108090000765 processed proteins & peptides Proteins 0.000 description 35
• 150000001413 amino acids Chemical class 0.000 description 30
• 108091033319 polynucleotide Proteins 0.000 description 19
• 102000040430 polynucleotide Human genes 0.000 description 19
• 239000002157 polynucleotide Substances 0.000 description 19
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 17
• 102000039446 nucleic acids Human genes 0.000 description 8
• 108020004707 nucleic acids Proteins 0.000 description 8
• 150000007523 nucleic acids Chemical class 0.000 description 8
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 102000004169 proteins and genes Human genes 0.000 description 7
• 108090000623 proteins and genes Proteins 0.000 description 7
• 125000003275 alpha amino acid group Chemical group 0.000 description 5
• 239000002773 nucleotide Substances 0.000 description 4
• 125000003729 nucleotide group Chemical group 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• 238000000034 method Methods 0.000 description 3
• 239000012472 biological sample Substances 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 206010011903 Deafness traumatic Diseases 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000001738 Nervous System Trauma Diseases 0.000 description 1
• 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000010886 Peripheral nerve injury Diseases 0.000 description 1
• 206010072170 Skin wound Diseases 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 208000028412 nervous system injury Diseases 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1